Helping patients find the prostate cancer
resources they deserve
How do we help prostate cancer patients?
Massive Bio offers an independent cancer treatment analysis as well as clinical trial matching for prostate cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a second opinion through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.
There are approximately 2,595 prostate cancer clinical trials that are currently patients in the United States right now. With such an extensive list, many of them could be beneficial for you. Our team of oncology nurses and our artificial intelligence based clinical trial matching system will find the best option for you.
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
With just a few clicks, you can see your clinical trial matches now. Click here to use our advanced clinical trial match tool.
Prostate Cancer Facts
Autopsy studies show that nearly one in three men who are over 50 have some cancerous cells in their prostate. African American men have Prostate Cancer more than any other ethnicity and nearly one in six people will be diagnosed.
Prostate Cancer only occurs in men. Typically, Prostate Cancer patients experience symptoms that involve changes and trouble with urinating, weight loss, and pain in the lower back. There is no known cause of Prostate Cancer but doctors have identified several risk factors. Family history plays a large role. If someone in your family has had Prostate Cancer, you are three times as likely to have Prostate Cancer at some point. Smoking makes you twice as likely to have Prostate Cancer as the average person. Diet can also play a role in the development of the cancer. Many doctors suggest that having a healthy heart means you will have a healthy prostate.
Treatment options for Prostate Cancer include:
Watchful waiting or active surveillance
Radiation therapy and radiopharmaceutical therapy
These treatment options are currently being used within clinical trials and are very beneficial for those who don’t respond well to typical treatment methods:
High-intensity–focused ultrasound therapy
Proton beam radiation therapy
There are a few standard screening methods to detect any signs relating to Prostate Cancer. The prostate-specific antigen (PSA) blood test measures the level of protein in the blood made by the prostate. Digital rectal examinations (DRE) help doctors detect any abnormalities in the rectum caused by the prostate. Finally, a biopsy can also be done to look for cancer cells under a microscope.
Prostate Cancer is not fatal for most patients considering The 5-year survival rate is 98%. However, there will be almost 175,000 new cases this year, which ranks third among all cancer types. In 1975, there were 94 cases per 100,000 people and there were 31 deaths per 100,000 people. In 2016, the number of cases has risen considerably, but the death rate has been nearly cut in half. There are 118 cases per 100,000 people and 19.4 deaths per 100,000 people.
Types of Prostate Cancer include:
Transitional cell (or urothelial) cancer
Squamous cell cancer
Small cell prostate cancer
Our team of patient advocates can help guide you to treatment options you might not have been previously aware of. Although you might be new to cancer, we certainly are not. Navigating cancer patients through the tricky path of finding the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for all of our patients based on their specific genomics, location, stage of cancer, and nearly 100 more data points.